Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimenrix (MenACWY) Dosing in Healthy Toddlers
NCT00471081Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2007
- Primary completion
- Oct 2008
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of meningococcal group A, C, W135 and Y conjugate vaccine in meningococcal infection (2 arms), sponsored by GSK. Primary endpoint: Serum Bactericidal Assay Using Human Complement Antibody Titers at Month 4. Started Jul 2007; status: completed.
02
Drugs
meningococcal group A, C, W135 and Y conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT00471081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471081.